References
- Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–3. doi: 10.1016/S0140-6736(20)32549-6.
- Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639. doi: 10.1159/000455840.
- Kiełbowski K, Bakinowska E, Ostrowski P, et al. The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci. 2023;24(7):6390. doi: 10.3390/ijms24076390.
- Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133(2):157–170. doi: 10.1016/j.clim.2009.07.013.
- Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2(6):318–327. doi: 10.1038/ncpendmet0196.
- Ruggiero A, Camela E, Potestio L, et al. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi: 10.1080/14740338.2022.2160447.
- Ruggiero A, Fabbrocicni G, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–536. doi: 10.2147/CCID.S402183.
- Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531.
- Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.
- Camela E, Potestio L, Fabbrocini G, et al. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–552. doi: 10.1080/13543784.2023.2219387.